We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
23andMe sets sights on UK/Canada, signs up Genentech.
- Authors
Mullard, Asher
- Abstract
The article reports that the biotechnology company 23andMe has launched its direct-to-consumer personal genetics service in Canada and Great Britain in 2014 and collaborated with the biotechnology firm with Genentech to provide whole genome sequence data for the discovery of drug for Parkinson's disease. It presents the views of Bill Newman, chair-elect for the British Society for Genetic Medicine, on direct-to-consumer patient testing in Great Britain.
- Subjects
23 &; Me Inc.; GENENTECH Inc.; DRUG development; PARKINSON'S disease; NEWMAN, Bill
- Publication
Nature Biotechnology, 2015, Vol 33, Issue 2, p119
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0215-119a